Camp4 Therapeutics Corp (CAMP) stock
CAMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3057% above fair value
$3.80−0.29 (-7.09%)
Close on Nov 13, 2026Market cap $238.46MP/E –Yield 0.00%
Camp4 Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
No total debt figures for Camp4 Therapeutics
Camp4 Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?